Plasma rich in growth factors for diabetic foot ulcers with poor leg circulation
Tests PRGF against usual care for healing foot ulcers in diabetic adults with artery disease.
Key facts
- Who runs it
- Biotechnology Institute IMASD
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 38 people, planned
- Started
- 1 Nov 2025
- Expected to end
- 30 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Topical application of Plasma Rich in Growth Factors (PRGF)
- Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
- Record updated
- 11 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or 2 diabetes who have a foot ulcer and poor blood flow in the legs (peripheral arterial disease). It compares PRGF, a treatment made from the patient's own blood, with conventional treatment.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- One or more ulcers below the ankle bones, 1 to 25 cm2 in size. Infection of the wound no higher than 1 on the IDSA/IWGDF scale. Ulcers grade 3 or higher cannot join.
- Earlier treatment
- People cannot join if they are on other local treatment at the ulcer, on immunosuppressants, on monoclonal antibodies, or on regular NSAIDs for 3 months or more (acetylsalicylic acid is allowed).
- Biomarker or test result
- At least 2 of: no foot or leg pulses on exam, ankle pressure 50-90 mmHg, toe pressure 30-70 mmHg, ABI 0.5-0.9, FIBI 0.3-0.7, TcPO2 30-59 mmHg. Glycosylated hemoglobin must not be above 9%.
Main reasons for not taking part
- Positive test for HCV, AfHBs, HIV-I/II or TP
- Active infection throughout the body
- Cancer or precancerous lesions in the treated area
- Allergy to blood products or a known blood clotting disorder
- Pregnancy, breastfeeding, or women who can become pregnant and do not use effective birth control
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Patients aged at least 18 years
- Diagnosis of type 1 or 2 diabetes
- Presence of one or more ulcers below the malleoli
- Ulcer size ranging from 1 to 25 cm2
- Peripheral Arterial Disease (PAD)
- Meet at least 2 of the following crieria:
- Absence of peripheral pulses at any level on physical examination of lower extremities
- Ankle pressure of 50-90 mmHg
- Finger pressure 30-70 mmHg
- Ankle-branchial index (ABI) 0.5-0.9
- Finger-arm index (FIBI) 0.3-0.7
- Transcutaneous oxygen pressure (TcPO2) 30-59 mmHg
- Degree of infection of the lesion on IDSA/IWGDF scale not greater than 1
- Availability of observation during the study period
- Properly completed patient informed consent
Who cannot take part
- On active treatment with other local treatment at the site of treatment
- On active treatment with immunosuppressants and/or other drugs contraindicating blood collection
- Previous diagnosis of coagulopathies
- Treatment with monoclonal antibodies
- Positive markers for HCV, AfHBs, HIV-I/II or TP
- Active systemic infection
- History of cancerous or precancerous lesions in the area of intervention
- History of allergy to blood derivatives
- Diabetes mellitus with poor metabolic control (evidence of glycosylated hemoglobin >9%)
- Pregnancy or women of chilbearig age not taking effective contraceptive measures. These methods are, according to recommendations of the Clinical Trial Facilitation Group (CTFG) Contraception Working Group (CTFG) (V1.1), the following Hormonal contraception associated with ovulation inhibition, intrauterine decide (IUD), intrauterine hormone-releasing system, bilateral tubal ligation, vasectomy partner, sexual abstinence
- Ulcers grade 3 or higher
- Regular and continuous treatment (≥ 3 months) with NSAIDs (with the exception of the use of acetylsalicilic acid)
- Breastfeeding women
- Any inabilities to participate in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease. The goal is to assess how well PRGF promotes healing over a six-month period.
The 2 groups in the trial
- Topical application of Plasma Rich in Growth Factors (PRGF)Treatment being tested
The Principal Investigator, or duly delegated qualified personnel, is responsible for the preparation using the KMU10-TPC Kit (BTI Biotechnology Institute, S.L.).
- Conventional treatment with adequate offloading and metabolic control, +/- antibiotic).Existing treatment, for comparison
Manufacturer: N/A
Treatment: Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Clinical Trial, Controlled With Conventional Treatment to Evaluate the Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
- Plain-language title
- Plasma rich in growth factors for diabetic foot ulcers with poor leg circulationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 11 September 2025